PwC

Global disruption, drug shortages, geopolitical risk, and cost pressures have pushed pharma supply chains into the spotlight. What was once an operational function is now a direct driver of revenue, launch success, and investor confidence. Pharmaceutical Executive® sat down with Rafael Lander, Principal, Pharmaceutical & Life Sciences Supply Chain and Operations at PwC US, to explore how leading pharma and biotech organizations are modernizing their supply chains to improve resilience, accelerate launches, and protect margins. This is all done without compromising compliance or patient service. From AI-enabled forecasting to digitally connected quality operations, this conversation covers what is delivering results today and where executives should place their focus.

Global disruption, drug shortages, geopolitical risk, and cost pressures have pushed pharma supply chains into the spotlight. What was once an operational function is now a direct driver of revenue, launch success, and investor confidence. Pharmaceutical Executive® sat down with Rafael Lander, Principal, Pharmaceutical & Life Sciences Supply Chain and Operations at PwC US, to explore how leading pharma and biotech organizations are modernizing their supply chains to improve resilience, accelerate launches, and protect margins. This is all done without compromising compliance or patient service. From AI-enabled forecasting to digitally connected quality operations, this conversation covers what is delivering results today and where executives should place their focus.

Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT

In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. While these third-party relationships can be full of risk and regulatory challenges, the right tech can help you navigate the complexities of compliance.

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, new systems were quickly — and possibly haphazardly — put in place to handle snowballing transparency reporting requirements. Now the cracks are beginning to show, and PLS companies are realizing the true cost of transparency reporting.